Efficacy and immunogenicity of a veterinary vaccine candidate
against tick-borne encephalitis in dogs

J 2023

Efficacy and immunogenicity of a veterinary vaccine candidate against tick-borne encephalitis in dogs

SALÁT, Jiří; Milan HUNADY; Pavel SVOBODA; Lucie STŘELCOVÁ; Petra STRAKOVÁ et al.

Základní údaje

Originální název

Efficacy and immunogenicity of a veterinary vaccine candidate against tick-borne encephalitis in dogs

Autoři

SALÁT, Jiří; Milan HUNADY; Pavel SVOBODA; Lucie STŘELCOVÁ; Petra STRAKOVÁ; Andrea FOŘTOVÁ; Martin PALUS a Daniel RŮŽEK

Vydání

Vaccine, Elsevier Ltd, 2023, 0264-410X

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

40301 Veterinary science

Stát vydavatele

Velká Británie a Severní Irsko

Utajení

není předmětem státního či obchodního tajemství

Odkazy

URL

Impakt faktor

Impact factor: 4.500

Označené pro přenos do RIV

Ano

Kód RIV

RIV/00216224:14310/23:00132670

Organizační jednotka

Přírodovědecká fakulta

Klíčová slova anglicky

Tick-borne encephalitis; Vaccine; Dogs

Štítky

14314010, rivok

Příznaky

Mezinárodní význam, Recenzováno

Změněno: 18. 1. 2024 10:44, Mgr. Marie Novosadová Šípková, DiS.

Anotace

V originále

Tick-borne encephalitis (TBE) is a severe neuroinfection of humans. Dogs are also commonly infected with tick-borne encephalitis virus (TBEV). These infections are usually asymptomatic, but sometimes show clinical signs similar to those seen in humans and can be fatal. To date, there is no TBEV vaccine available for use in dogs. To address this need, a TBEV vaccine candidate for dogs based on inactivated whole virus antigen was developed. The safety, immunogenicity, and efficacy of the vaccine candidate were tested in mice as the preclinical model and in dogs as the target organism. The vaccine was well tolerated in both species and elicited the production of specific anti-TBEV antibodies with virus neutralising activity. Vaccination of mice provided complete protection against the development of fatal TBE. Immunisation of dogs prevented the development of viremia after challenge infection. Therefore, the developed vaccine candidate is promising to protect dogs from severe TBEV infections.

Návaznosti

LM2018127, projekt VaV

Název: Česká infrastruktura pro integrativní strukturní biologii (Akronym: CIISB)

Investor: Ministerstvo školství, mládeže a tělovýchovy ČR, Czech Infrastructure for Integrative Structural Biology

Citovat

SALÁT, Jiří; Milan HUNADY; Pavel SVOBODA; Lucie STŘELCOVÁ; Petra STRAKOVÁ; Andrea FOŘTOVÁ; Martin PALUS a Daniel RŮŽEK. Efficacy and immunogenicity of a veterinary vaccine candidate against tick-borne encephalitis in dogs. Vaccine. Elsevier Ltd, 2023, roč. 41, č. 42, s. 6150-6155. ISSN 0264-410X. Dostupné z: https://doi.org/10.1016/j.vaccine.2023.09.019.

@article{2353803,
   author = {Salát, Jiří and Hunady, Milan and Svoboda, Pavel and Střelcová, Lucie and Straková, Petra and Fořtová, Andrea and Palus, Martin and Růžek, Daniel},
   article_number = {42},
   doi = {https://doi.org/10.1016/j.vaccine.2023.09.019},
   keywords = {Tick-borne encephalitis; Vaccine; Dogs},
   language = {eng},
   issn = {0264-410X},
   journal = {Vaccine},
   title = {Efficacy and immunogenicity of a veterinary vaccine candidate against tick-borne encephalitis in dogs},
   url = {https://doi.org/10.1016/j.vaccine.2023.09.019},
   volume = {41},
   year = {2023}
}

TY  - JOUR
ID  - 2353803
AU  - Salát, Jiří - Hunady, Milan - Svoboda, Pavel - Střelcová, Lucie - Straková, Petra - Fořtová, Andrea - Palus, Martin - Růžek, Daniel
PY  - 2023
TI  - Efficacy and immunogenicity of a veterinary vaccine candidate against tick-borne encephalitis in dogs
JF  - Vaccine
VL  - 41
IS  - 42
SP  - 6150-6155
EP  - 6150-6155
PB  - Elsevier Ltd
SN  - 0264410X
KW  - Tick-borne encephalitis
KW  - Vaccine
KW  - Dogs
UR  - https://doi.org/10.1016/j.vaccine.2023.09.019
N2  - Tick-borne encephalitis (TBE) is a severe neuroinfection of humans. Dogs are also commonly infected with tick-borne encephalitis virus (TBEV). These infections are usually asymptomatic, but sometimes show clinical signs similar to those seen in humans and can be fatal. To date, there is no TBEV vaccine available for use in dogs. To address this need, a TBEV vaccine candidate for dogs based on inactivated whole virus antigen was developed. The safety, immunogenicity, and efficacy of the vaccine candidate were tested in mice as the preclinical model and in dogs as the target organism. The vaccine was well tolerated in both species and elicited the production of specific anti-TBEV antibodies with virus neutralising activity. Vaccination of mice provided complete protection against the development of fatal TBE. Immunisation of dogs prevented the development of viremia after challenge infection. Therefore, the developed vaccine candidate is promising to protect dogs from severe TBEV infections.
ER  -

SALÁT, Jiří; Milan HUNADY; Pavel SVOBODA; Lucie STŘELCOVÁ; Petra STRAKOVÁ; Andrea FOŘTOVÁ; Martin PALUS a Daniel RŮŽEK. Efficacy and immunogenicity of a veterinary vaccine candidate against tick-borne encephalitis in dogs. \textit{Vaccine}. Elsevier Ltd, 2023, roč.~41, č.~42, s.~6150-6155. ISSN~0264-410X. Dostupné z: https://doi.org/10.1016/j.vaccine.2023.09.019.

Přehled o publikaci